Boston Family Office’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Boston Family Office’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-24,197	Closed	-$73K	–	278
2024 Q1	$73K	Hold	24,197	–	–	0.01%	262
2023 Q4	$74K	Hold	24,197	–	–	0.01%	258
2023 Q3	$69K	Hold	24,197	–	–	0.01%	252
2023 Q2	$62K	Buy	+24,197	New	+$50.7K	﹤0.01%	259

Boston Family Office's CYT Position: Q2 2024 in Review

Boston Family Office sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2024, closing a stake of 24,197 shares — an estimated $73K sold.

Boston Family Office first reported a position in CYT in Q2 2023 and held it in 4 quarters. The position peaked at $74K in Q4 2023. 0 funds tracked by Wall St. Rank hold CYT as of Q2 2024.

Boston Family Office reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Boston Family Office sold 24,197 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $73K.
Boston Family Office first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2023 and held it in 4 quarters.
Boston Family Office's Cyteir Therapeutics, Inc. Common Stock position peaked at $74K in Q4 2023.
0 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Boston Family Office's 13F filing for Q2 2024, filed 12 Aug 2024.